Updated BEXMAB Phase I/II Data Presented at ESMO 2025 Shows Further Improvement, Strengthening the Clinical Profile of Bexmarilimab in Treatment-Naïve HR-MDS Patients

About this update from Faron Pharmaceuticals Oy

[{"type":"text","content":"TURKU, FI / ACCESS Newswire / October 20, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharmacodynamic insights","length":334,"tagName":"p"},{"type":"text","content":"New biomarker data reveals strong correlation between target engagement and clinical response with 100% ORR in treatment-naïve, low blast count (<5%) patients","length":161,"tagName":"p"},{"type":"text","content":"Key highlights:","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Bexmarilimab and azacitidine combination resulted in an 85% objective response rate (ORR; 17/20 evaluable patients) and a 45% complete remission (CR) rate (9/20) in treatment-naïve patients with higher-risk myelodysplastic syndrome (HR-MDS)","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"55% (11/20) of treatment-naïve patients with HR-MDS showed full clearance of bone marrow (BM) blasts","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Deeper BM engagement in treatment-naïve patients with <5% bone marrow blasts at baseline translated to 100% ORR, one of the best results ever reported in this patient population","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"23% of patients across the BEXMAB study were successfully bridged to a potentially curative stem cell transplant (SCT)","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"Faron will be hosting a virtual webinar to discuss the updated BEXMAB data presented at ESMO 2025 on 23 October at 4pm EEST/9am ET.","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":769,"olType":false},{"type":"text","content":"Turku, Finland- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announced that updated data from the Phase I/II BEXMAB study continues to show significant clinical activity for bexmarilimab. The findings, presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2025 by Dr. Mika Kontro from Helsinki University Hospital, not only confirm the high respo...

More updates from Faron Pharmaceuticals Oy